Overview
Prospective, observational cohort study of patients undergoing surgical resection for low dose CT (LDCT) screen-detected lung cancer (detected through the SUMMIT studyClinicalTrials. gov Identifier: NCT03934866/ lung screening programmes), in which translational research is a fundamental aspect.
Description
The ASCENT study seeks to examine the genomic signatures of screen-detected cancers, in order to categorise the biological behaviour of such lesions and correlate this against non-invasive biological and radiological parameters. From these data, the plan is to explore strategies to characterise LDCT-detected cancers through non-invasive means, which the researchers believe may prove key in mitigating potential screening-associated harms.
Eligibility
Inclusion Criteria:
- Diagnosed with confirmed lung cancer or probable lung cancer via LDCT screening.
- Planned for, or completed primary surgical resection either for histologically confirmed lung cancer, or strongly suspected lung cancer.
- Able to provide written informed consent (or verbal informed consent for participants consenting to retrospective diagnostic samples and data collection only).
Exclusion Criteria:
- Treatment with neoadjuvant therapy for current lung malignancy as per local MDT treatment decision.
- Known Active Human Immunodeficiency Virus (HIV), Hepatitis B virus, Hepatitis C Virus or Syphilis.